View on GitHub

Pistoia-Alliance-PGO

Pistoia Alliance Pharma General Ontology - One, shared and maintained upper level reference ontology for Pharma.

Class: Protein

A linear polymer of amino acids joined by peptide bonds in a specific sequence. https://www.ebi.ac.uk/ols4/ontologies/mi/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FMI_0326

Alternative Descriptions * pro_definition | | * mesh_definition | |
Aliases
Examples | Value | Description | --- | --- | | [tumor protein p53](https://www.wikidata.org/wiki/Q283350) | an example of a protein | | [Cadherin-3](https://www.uniprot.org/uniprot/P22223) | an example of a protein belonging to the cadherin family |
Annotations | property | value | | --- | --- | | definition_source | https://www.ebi.ac.uk/ols4/ontologies/mi/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FMI_0326 | | definition_source_attribution | Molecular Interactions (MI) | | definition_source_licence | [CC-BY-4.0](https://creativecommons.org/licenses/by/4.0/) | | definition_access_date | 2025-06-09 | | expert_approval_date | 2025-03-12 | | conceptual_clarification | Key areas of definitional variation highlighted by PGO partners include-- 1. Synthesis route – a distinction between naturally occurring and synthetically produced proteins. 2. Functional role – ambiguity over whether proteins should be classified as therapeutic agents (e.g., monoclonal antibodies). 3. Ontological role – whether a protein is conceptualized as a substance or as a target entity in biomedical contexts. Further, the IDMP Ontology (IDMP-O) defines 'protein substance' as 'a single substance with a defined sequence of alpha-amino acids connected through peptide bonds' (https--//spec.pistoiaalliance.org/idmp/ontology/ISO/ISO11238-Substances/ProteinSubstance). However, this specification-oriented approach may limit its utility for the broader semantic scope required by PGO. The relevance of adjacent domains, such as production, was also noted. Organizational perspectives added additional nuances-- * AstraZeneca (AZ) provides a classical biochemical definition, emphasizing proteins as nitrogenous organic compounds comprising amino acid chains, critical to structural and enzymatic functions, though no URI was provided. * Roche offers a more ontologically grounded definition, adapted from NCIt, focusing on proteins as genetically encoded entities with specific structural and functional properties, ranging significantly in molecular weight. |
Comments * During the meetings held on 1st and 15th August 2024, participants reviewed multiple definitions of 'protein' from various ontological and organizational sources to inform the PGO initiative's conceptual alignment. A majority of funding partners (three out of the group) expressed preference for the NCI Thesaurus ID-- C17021 (http--//purl.obolibrary.org/obo/NCIT_C17021), which was recognized as providing a broadly applicable and general definition of proteins. However, discussions also identified several limitations and points of divergence related to this definition. * Key areas of definitional variation highlighted by PGO partners include--1.Synthesis route – a distinction between naturally occurring and synthetically produced proteins. 2.Functional role – ambiguity over whether proteins should be classified as therapeutic agents (e.g., monoclonal antibodies). 3.Ontological role – whether a protein is conceptualized as a substance or as a target entity in biomedical contexts. Further, the IDMP Ontology (IDMP-O) defines 'protein substance' as 'a single substance with a defined sequence of alpha-amino acids connected through peptide bonds' (https--//spec.pistoiaalliance.org/idmp/ontology/ISO/ISO11238-Substances/ProteinSubstance). However, this specification-oriented approach may limit its utility for the broader semantic scope required by PGO. The relevance of adjacent domains, such as production, was also noted. * Organizational perspectives added additional nuances-- * AstraZeneca (AZ) provides a classical biochemical definition, emphasizing proteins as nitrogenous organic compounds comprising amino acid chains, critical to structural and enzymatic functions, though no URI was provided. * Roche offers a more ontologically grounded definition, adapted from NCIt, focusing on proteins as genetically encoded entities with specific structural and functional properties, ranging significantly in molecular weight. * The follow-up meeting on 15th August 2024 identified specific issues with NCIT_C17021, such as its focus on naturally occurring proteins, plural group-level semantics, and explicit mention of L- versus D-amino acids. As an alternative, PR--000000001 (Protein Ontology) was discussed, which defines a protein as 'an amino acid chain produced de novo by ribosome-mediated translation of genetically-encoded mRNA,' though its emphasis on natural biosynthesis was seen as a constraint. There was a general consensus among experts to prefer definitions that describe the intrinsic substance-based identity of proteins, rather than definitions constrained by the method of synthesis. The definition of 'protein' from the Molecular Interactions controlled vocabulary was noted for its general applicability, broad expert support, and compatibility with existing ontologies such as IDMP-O. It represented the most favored formulation within the expert group. * Proposal and Recommendation to the PGO steering committee 1. Adopt the Molecular Interactions controlled vocabulary for the definiton of 'Protein' , namely-- 'A linear polymer of amino acids joined by peptide bonds in a specific sequence'.
TODOs ## TODOs * Review preferred sources